Do analysts rate SYBX or CNTX?

Context Therapeutics has a consensus target price of $6.17, indicating a potential upside of 1,079.32%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Context Therapeutics is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Context Therapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Is SYBX or CNTX more profitable?

Synlogic's return on equity of -26.47% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Synlogic N/A -26.47% -18.00% Context Therapeutics N/A -82.06% -72.74%

Does the media refer more to SYBX or CNTX?

In the previous week, Context Therapeutics had 10 more articles in the media than Synlogic. MarketBeat recorded 11 mentions for Context Therapeutics and 1 mentions for Synlogic. Synlogic's average media sentiment score of 1.08 beat Context Therapeutics' score of 0.51 indicating that Synlogic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synlogic 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Context Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SYBX or INKT?

MiNK Therapeutics has a consensus price target of $35.00, indicating a potential upside of 210.56%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe MiNK Therapeutics is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MiNK Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is SYBX or INKT more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Synlogic's return on equity. Company Net Margins Return on Equity Return on Assets Synlogic N/A -26.47% -18.00% MiNK Therapeutics N/A N/A -86.10%

Does the media refer more to SYBX or INKT?

In the previous week, MiNK Therapeutics had 11 more articles in the media than Synlogic. MarketBeat recorded 12 mentions for MiNK Therapeutics and 1 mentions for Synlogic. Synlogic's average media sentiment score of 1.08 beat MiNK Therapeutics' score of -0.45 indicating that Synlogic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synlogic 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiNK Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend SYBX or INO?

Inovio Pharmaceuticals has a consensus target price of $3.17, suggesting a potential upside of 190.52%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Inovio Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75

Is SYBX or INO more profitable?

Synlogic's return on equity of -26.47% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Synlogic N/A -26.47% -18.00% Inovio Pharmaceuticals N/A -669.94% -73.97%

Does the media prefer SYBX or INO?

In the previous week, Inovio Pharmaceuticals had 15 more articles in the media than Synlogic. MarketBeat recorded 16 mentions for Inovio Pharmaceuticals and 1 mentions for Synlogic. Synlogic's average media sentiment score of 1.08 beat Inovio Pharmaceuticals' score of 0.72 indicating that Synlogic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synlogic 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inovio Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ATYR or SYBX?

aTyr Pharma currently has a consensus target price of $17.00, indicating a potential upside of 2,941.14%. Given aTyr Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe aTyr Pharma is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ATYR or SYBX more profitable?

Synlogic's return on equity of -26.47% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -95.89% -69.67% Synlogic N/A -26.47% -18.00%

Does the media prefer ATYR or SYBX?

In the previous week, aTyr Pharma had 14 more articles in the media than Synlogic. MarketBeat recorded 15 mentions for aTyr Pharma and 1 mentions for Synlogic. Synlogic's average media sentiment score of 1.08 beat aTyr Pharma's score of 0.83 indicating that Synlogic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Synlogic 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SYBX or EDSA?

Edesa Biotech has a consensus target price of $5.00, suggesting a potential downside of 6.54%. Given Edesa Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Edesa Biotech is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is SYBX or EDSA more profitable?

Synlogic's return on equity of -26.47% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Synlogic N/A -26.47% -18.00% Edesa Biotech N/A -437.50% -104.14%

Does the media refer more to SYBX or EDSA?

In the previous week, Edesa Biotech had 6 more articles in the media than Synlogic. MarketBeat recorded 7 mentions for Edesa Biotech and 1 mentions for Synlogic. Synlogic's average media sentiment score of 1.08 beat Edesa Biotech's score of 0.18 indicating that Synlogic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synlogic 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edesa Biotech 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Synlogic (SYBX) Competitors

$1.22 -0.01 (-0.81%)

As of 03:04 PM Eastern

Compare

SYBX vs. CNTX, INKT, INO, ATYR, and EDSA

Should you buy Synlogic stock or one of its competitors? Synlogic's main competitors and comparable companies include Context Therapeutics (CNTX), MiNK Therapeutics (INKT), Inovio Pharmaceuticals (INO), aTyr Pharma (ATYR), and Edesa Biotech (EDSA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Synlogic compare to Context Therapeutics?

Synlogic (NASDAQ:SYBX) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Context Therapeutics has a consensus target price of $6.17, indicating a potential upside of 1,079.32%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Context Therapeutics is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Synlogic has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market.

In the previous week, Context Therapeutics had 10 more articles in the media than Synlogic. MarketBeat recorded 11 mentions for Context Therapeutics and 1 mentions for Synlogic. Synlogic's average media sentiment score of 1.08 beat Context Therapeutics' score of 0.51 indicating that Synlogic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synlogic	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Context Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Synlogic has higher revenue and earnings than Context Therapeutics. Synlogic is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,867.97	-$23.36M	-$0.06	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

Synlogic's return on equity of -26.47% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
Context Therapeutics	N/A	-82.06%	-72.74%

63.4% of Synlogic shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 2.6% of Synlogic shares are held by insiders. Comparatively, 4.8% of Context Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Synlogic and Context Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Synlogic compare to MiNK Therapeutics?

Synlogic (NASDAQ:SYBX) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

63.4% of Synlogic shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 2.6% of Synlogic shares are held by company insiders. Comparatively, 20.4% of MiNK Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MiNK Therapeutics has a consensus price target of $35.00, indicating a potential upside of 210.56%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe MiNK Therapeutics is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Synlogic has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

In the previous week, MiNK Therapeutics had 11 more articles in the media than Synlogic. MarketBeat recorded 12 mentions for MiNK Therapeutics and 1 mentions for Synlogic. Synlogic's average media sentiment score of 1.08 beat MiNK Therapeutics' score of -0.45 indicating that Synlogic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synlogic	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiNK Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

MiNK Therapeutics has lower revenue, but higher earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,867.97	-$23.36M	-$0.06	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A

MiNK Therapeutics' return on equity of 0.00% beat Synlogic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
MiNK Therapeutics	N/A	N/A	-86.10%

Summary

MiNK Therapeutics beats Synlogic on 7 of the 13 factors compared between the two stocks.

How does Synlogic compare to Inovio Pharmaceuticals?

Synlogic (NASDAQ:SYBX) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

Synlogic has higher earnings, but lower revenue than Inovio Pharmaceuticals. Synlogic is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,867.97	-$23.36M	-$0.06	N/A
Inovio Pharmaceuticals	$60K	1,878.43	-$84.95M	-$1.45	N/A

Inovio Pharmaceuticals has a consensus target price of $3.17, suggesting a potential upside of 190.52%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Inovio Pharmaceuticals had 15 more articles in the media than Synlogic. MarketBeat recorded 16 mentions for Inovio Pharmaceuticals and 1 mentions for Synlogic. Synlogic's average media sentiment score of 1.08 beat Inovio Pharmaceuticals' score of 0.72 indicating that Synlogic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synlogic	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inovio Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Synlogic has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

63.4% of Synlogic shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 2.6% of Synlogic shares are held by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Synlogic's return on equity of -26.47% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%

Summary

Inovio Pharmaceuticals beats Synlogic on 9 of the 16 factors compared between the two stocks.

How does Synlogic compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and Synlogic (NASDAQ:SYBX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by insiders. Comparatively, 2.6% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Synlogic has lower revenue, but higher earnings than aTyr Pharma. Synlogic is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	288.59	-$74.12M	-$0.62	N/A
Synlogic	$8K	1,867.97	-$23.36M	-$0.06	N/A

aTyr Pharma currently has a consensus target price of $17.00, indicating a potential upside of 2,941.14%. Given aTyr Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe aTyr Pharma is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Synlogic's return on equity of -26.47% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-95.89%	-69.67%
Synlogic	N/A	-26.47%	-18.00%

aTyr Pharma has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Synlogic has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

In the previous week, aTyr Pharma had 14 more articles in the media than Synlogic. MarketBeat recorded 15 mentions for aTyr Pharma and 1 mentions for Synlogic. Synlogic's average media sentiment score of 1.08 beat aTyr Pharma's score of 0.83 indicating that Synlogic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Synlogic	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

aTyr Pharma beats Synlogic on 9 of the 16 factors compared between the two stocks.

How does Synlogic compare to Edesa Biotech?

Synlogic (NASDAQ:SYBX) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

Synlogic has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Synlogic's return on equity of -26.47% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
Edesa Biotech	N/A	-437.50%	-104.14%

Edesa Biotech has lower revenue, but higher earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,867.97	-$23.36M	-$0.06	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

Edesa Biotech has a consensus target price of $5.00, suggesting a potential downside of 6.54%. Given Edesa Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Edesa Biotech is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

63.4% of Synlogic shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 2.6% of Synlogic shares are held by insiders. Comparatively, 24.4% of Edesa Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Edesa Biotech had 6 more articles in the media than Synlogic. MarketBeat recorded 7 mentions for Edesa Biotech and 1 mentions for Synlogic. Synlogic's average media sentiment score of 1.08 beat Edesa Biotech's score of 0.18 indicating that Synlogic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synlogic	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edesa Biotech	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Edesa Biotech beats Synlogic on 9 of the 15 factors compared between the two stocks.

Get Synlogic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SYBX vs. The Competition

Export

Metric	Synlogic	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.94M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-4.69	10.67	269.06	25.28
Price / Sales	1,867.97	1,262.99	592.57	87.62
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	1.12	16.78	12.91	6.24
Net Income	-$23.36M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-0.81%	1.74%	1.12%	1.07%
1 Month Performance	71.59%	1.60%	1.79%	1.03%
1 Year Performance	-15.86%	56.43%	67.69%	20.77%

Synlogic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYBX Synlogic	0.2704 of 5 stars	$1.22 -0.8%	N/A	-18.0%	$14.94M	$8K	N/A	80	Positive News
CNTX Context Therapeutics	2.9588 of 5 stars	$0.69 +11.5%	$6.17 +789.9%	-27.7%	$57.13M	N/A	N/A	7
INKT MiNK Therapeutics	2.7104 of 5 stars	$11.70 +5.7%	$35.00 +199.1%	-37.1%	$55.15M	N/A	N/A	30	Trending News Earnings Report Analyst Downgrade
INO Inovio Pharmaceuticals	3.2927 of 5 stars	$0.68 +2.1%	$3.25 +380.1%	-47.1%	$54.56M	$60K	N/A	320	News Coverage Earnings Report Analyst Upgrade Analyst Revision Gap Up
ATYR aTyr Pharma	2.7557 of 5 stars	$0.53 0.0%	$17.00 +3,113.6%	-89.3%	$51.89M	$190K	N/A	53	Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SYBX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synlogic (SYBX) Competitors

SYBX vs. CNTX, INKT, INO, ATYR, and EDSA

How does Synlogic compare to Context Therapeutics?

Summary

How does Synlogic compare to MiNK Therapeutics?

Summary

How does Synlogic compare to Inovio Pharmaceuticals?

Summary

How does Synlogic compare to aTyr Pharma?

Summary

How does Synlogic compare to Edesa Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYBX vs. The Competition

Synlogic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synlogic (SYBX) Competitors

SYBX vs. CNTX, INKT, INO, ATYR, and EDSA

How does Synlogic compare to Context Therapeutics?

Do analysts rate SYBX or CNTX?

Which has more risk & volatility, SYBX or CNTX?

Does the media refer more to SYBX or CNTX?

Which has higher valuation & earnings, SYBX or CNTX?

Is SYBX or CNTX more profitable?

Do insiders and institutionals believe in SYBX or CNTX?

Summary

How does Synlogic compare to MiNK Therapeutics?

Do institutionals & insiders believe in SYBX or INKT?

Do analysts rate SYBX or INKT?

Which has more risk and volatility, SYBX or INKT?

Does the media refer more to SYBX or INKT?

Which has preferable valuation and earnings, SYBX or INKT?

Is SYBX or INKT more profitable?

Summary

How does Synlogic compare to Inovio Pharmaceuticals?

Which has better earnings and valuation, SYBX or INO?

Do analysts recommend SYBX or INO?

Does the media prefer SYBX or INO?

Which has more risk & volatility, SYBX or INO?

Do institutionals and insiders have more ownership in SYBX or INO?

Is SYBX or INO more profitable?

Summary

How does Synlogic compare to aTyr Pharma?

Do insiders and institutionals have more ownership in ATYR or SYBX?

Which has preferable valuation and earnings, ATYR or SYBX?

Do analysts rate ATYR or SYBX?

Is ATYR or SYBX more profitable?

Which has more risk and volatility, ATYR or SYBX?

Does the media prefer ATYR or SYBX?

Summary

How does Synlogic compare to Edesa Biotech?

Which has more risk and volatility, SYBX or EDSA?

Is SYBX or EDSA more profitable?

Which has stronger valuation & earnings, SYBX or EDSA?

Do analysts recommend SYBX or EDSA?

Do institutionals and insiders hold more shares of SYBX or EDSA?

Does the media refer more to SYBX or EDSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYBX vs. The Competition

Synlogic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools